Compare Oscar Health Inc (OSCR) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oscar Health Inc vs Zoetis Inc — how do they compare? Oscar Health Inc trades at $33.37 (market cap $10.22B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 3× Oscar Health Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oscar Health Inc for 15 Days and Zoetis Inc for 70 Days on average.
| OSCR | ZTS | |
|---|---|---|
Market Cap | $10.22B | $30.20B |
Volume | 4,123,394 | 6,175,327 |
Sector | Health | Health |
52-Week High | $33.81 | $147.53 |
52-Week Low | $10.85 | $69.09 |
Typical Hold Time | 15 Days | 70 Days |
Enterprise Value | $6.57B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OSCR trades at $33.37, up 1.4% with strong technical momentum and bullish moving averages. The company shows impressive revenue growth from $11.7B in 2025 to $15.3B in 2026, turning profitable with $551M net income. Recent Q1 and Q2 2026 earnings beat expectations, while analyst consensus leans toward Hold (61.54%) with a $34 price target. Technical indicators show bullish signals but RSI suggests potential overbought conditions near-term.
Outlook remains positive with scalable ACA market growth and margin expansion driving earnings potential. Key risks include rising medical costs threatening profitability and competitive pressures. The stock offers growth exposure but requires monitoring of execution on 2029 EPS targets of $4+ and medical loss ratio management.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
